Friday, 27 Mar 2020

You are here

Sprifermin Benefits Cartilage Loss but not Symptoms in Knee Osteoarthritis

Intra-articular sprifermin given to patients with symptomatic and radiographic knee osteoarthritis has been shown to significantly improve total femorotibial joint cartilage thickness after 2 years, but without significant clinical beneftis. Which begs the question, why is there a disconnect between radiographic disease modification (cartilage thickness) and symptomatic improvement?

Sprifermin, recombinant human fibroblast growth factor 18 (rhFGF18) (insulin-like growth factor 1 bone morphogenetic protein 7), is being developed as a potential anabolic disease-modifying agent for osteoarthritis (DMOAD).

The FORWARD trial enrolled 549 participants who were randomized to 30 μg or 100 μg of sprifermin every 6 or 12 months vs placebo.

Spifermin was given four ways - 100 μg of sprifermin every 6 months (n = 110) or every 12 months (n = 110), or 30 μg of sprifermin every 6 months (n = 111) or every 12 months (n = 110), and placebo every 6 months (n = 108). Each treatment consisted of weekly injections over 3 weeks. The primary end point was change in total femorotibial joint cartilage thickness measured by quantitative magnetic resonance imaging at 2 years.

At 2 years, 86.3% completed the 2-year follow-up. Compared with placebo, the changes from baseline to 2 years in total femorotibial joint cartilage thickness was:

  • 100 μg every 6 months - 0.05 mm (95% CI, 0.03 to 0.07 mm)
  • 100 μg every 12 months - 0.04 mm (95% CI, 0.02 to 0.06 mm)
  • 30 μg every 6 months - 0.02 mm (95% CI, −0.01 to 0.04 mm)
  • 30 μg every 12 months 0.01 mm (95% CI, −0.01 to 0.03 mm)

Clinically, there were no statistically significant changes from total WOMAC scores when comparing sprifermin vs. PBO.

It is unclear what benefit may ensue from MRI improvements without clinical benefits.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Diabetes in OA: Pain Is Worse

Among patients with knee osteoarthritis (OA), pain was greater for those with coexisting diabetes mellitus (DM), and this association was independent of obesity and radiographic severity, European researchers found. 

JAK Inhibitors Stimulate Osteoblasts

Science Translational Medicine has a report on how the use of Janus kinase (JAK) inhibitors may boost osteoblasts to battle bone erosions in conditions like rheumatoid arthritis (RA).

JAK inhibitors have been shown in clinical trials to retard the development of bone erosions while controlling RA inflammation and other clinical features.

Hormone Therapy for Postmenopausal Women

The NEJM weighs in on the problem of post-menopausal osteoporosis (OP) and tackles the use of hormonal therapy. The decline in estrogen after menopause may increase risks for osteoporosis, cardiovascular disease, and cognitive decline. The use of hormone replacement therapy (HRT) to obviate these issues may be primarily driven by hot flashes in postmenopausal women.1 Who may benefit from hormone therapy among postmenopausal women?

Knee Replacements Last 25 Years

UK registry reports that greater than 80% of total knee replacements can last for 25 years.

The outcomes regarding the duration and durability of knee arthroplasties is sketchy, with many orthopedists projecting a 15 to 20 year survivial. Hence the need for an appraisal of the data.

Should We Screen Younger Postmenopausal Women for Osteoporosis?

Do postmenopausal women, under age 65 years, need a baseline BMD testing? A JAMA Insights review suggests that the absolute risk of fracture is low in this group and that USPSTF guidelines should be considered - that we should be screening women younger than 65 years who are at increased risk of osteoporosis and we should be using a formal risk assessment tool to identify candidates for bone density testing.